Recurrent high-grade glioma

Current Treatment Options in Neurology

Volumn 12, Issue 4, 2010, Pages 321-333

  Quant, Eudocia C ^a   Drappatz, Jan ^a   Wen, Patrick Y ^a   Norden, Andrew D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARMUSTINE; GLIADEL WAFER; IRINOTECAN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ALOPECIA; BLEEDING; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER GRADING; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG CONTRAINDICATION; DRUG COST; DRUG INDUCED DISEASE; DRUG TARGETING; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; HEADACHE; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; LIVER TOXICITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; PROTEINURIA; RADIATION DOSE; RADIATION NECROSIS; RECURRENT CANCER; REOPERATION; REVIEW; STEREOTACTIC RADIOSURGERY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; VOMITING; WOUND HEALING IMPAIRMENT;

EID: 77956393265     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-010-0078-5     Document Type: Review

References (49)

1. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2005. Hinsdale, IL: CBTRUS; 2009. Available at http://www.cbtrus.org/reports/2009- NPCR-04-05/CBTRUS-NPCR2004- 2005-Report-.pdf. Accessed October 2009.
2. Lamborn KR, Yung WK, Chang SM, et al.: Progression- free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008, 10:162-170.
3. Wong ET, Hess KR, Gleason MJ, et al.: Outcomes and prognostic factors in recurrent glioma patients en- rolled onto phase II clinical trials. J Clin Oncol 1999, 17:2572-2578.
4. Wen PY, Kesari S: Malignant gliomas in adults. N Engl J Med 2008, 359:492-507. This review provides an overview of the pathology, biology, and treatment of HGGs
5. Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8:1277-1280.
6. Henson JW, Ulmer S, Harris GJ: Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008, 29:419-424.
7. Sorensen AG, Batchelor TT, Wen PY, et al.: Response criteria for glioma. Nat Clin Pract Oncol 2008, 5:634-644.
8. van den Bent MJ, Vogelbaum MA, Wen PY, et al.: End point assessment in gliomas: Novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 2009, 27:2905-2908.
9. Wen PY, Macdonald DR, Reardon DA, et al.: Updated response assessment criteria for highgrade gliomas: Response Assessment in Neuro- Oncology Working Group. J Clin Oncol 2010, 28 (11):1963-1972. This article outlines the proposed changes to response criteria used in clinical trials for HGGs
10. Butowski NA, Sneed PK, Chang SM: Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol 2006, 24:1273-1280.
11. Chamberlain MC, Glantz MJ, Chalmers L, et al.: Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007, 82:81-83.
12. Park DM, Rich JN: Biology of glioma cancer stem cells. Mol Cells 2009, 28:7-12.
13. Friedman HS, Prados MD, Wen PY, et al.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740. This noncomparative phase 2 clinical trial of bevacizumab with and without irinotecan played a role in FDA approval for bevacizumab in patients with recurrent glioblastoma
14. Kreisl TN, Kim L, Moore K, et al.: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27:740- 745.This phase 2 clinical trial of bevacizumab monotherapy played a role in FDA approval for bevacizumab in patients with recurrent glioblastoma
15. Brandes AA, Tosoni A, Amista P, et al.: How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 2004, 63:1281-1284.
16. Brem H, Piantadosi S, Burger PC, et al.: Placebocontrolled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group Lancet 1995, 345:1008-1012.
17. Vredenburgh JJ, Desjardins A, Herndon 2nd JE, et al.: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13:1253-1259.
18. Vredenburgh JJ, Desjardins A, Herndon 2nd JE, et al.: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729.
19. Norden AD, Drappatz J, Wen PY: Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008, 7:1152-1160.
20. Villano JL, Seery TE, Bressler LR: Temozolomide in malignant gliomas: Current use and future targets. Cancer Chemother Pharmacol 2009, 64:647-655.
21. National Comprehensive Cancer Network: Central Nervous System Cancers. Available at http://www. nccn.org/professionals/physician-gls/PDF/cns.pdf. Accessed December 1, 2009.
22. Yung WK, Prados MD, Yaya-Tur R, et al.: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999, 17:2762-2771.
23. Desjardins A, Reardon DA, Herndon 2nd JE, et al.: Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008, 14:7068-7073.
24. Brada M, Gabe R, Stenning S, et al.: A randomised trial of temozolomide vs PCV chemotherapy for recurrent malignant glioma (MRC BR12) [abstract]. Presented at the 33rd European Society for Medical Oncology (ESMO) Congress. Stockholm, Sweden; September 12-16, 2008.
25. Wick W, Hartmann C, Engel C, et al.: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009, 27:5874-5880. This randomized phase 3 clinical trial investigates the sequence of treatment (radiation followed by chemotherapy vs chemotherapy followed by radiation) in patients with anaplastic glioma.
26. Cairncross G, Macdonald D, Ludwin S, et al.: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994, 12:2013-2021.
27. Soffietti R, Ruda R, Bradac GB, Schiffer D: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998, 43:1066-1073.
28. Chinot OL, Honore S, Dufour H, et al.: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001, 19:2449-2455.
29. van den Bent MJ, Chinot O, Boogerd W, et al.: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 2003, 14:599-602.
30. van den Bent MJ, Taphoorn MJ, Brandes AA, et al.: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003, 21:2525-2528.
31. Bota DA, Desjardins A, Quinn JA, et al.: Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. Ther Clin Risk Manag 2007, 3:707-715.
32. Mayer R, Sminia P: Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys 2008, 70:1350-1360.
33. Nieder C, Astner ST, Mehta MP, et al.: Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 2008, 31:300-305.
34. Combs SE, Debus J, Schulz-Ertner D: Radiotherapeutic alternatives for previously irradiated recurrent gliomas. BMC Cancer 2007, 7:167.
35. Gutin PH, Iwamoto FM, Beal K, et al.: Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009, 75:156-163.
36. Alexander 3rd E: Glioblastoma revisited: Do clinical observations match basic science theory? Radiosurgery: Clinical observations. J Neurooncol 1993, 17:167-173.
37. Cho KH, Hall WA, Gerbi BJ, et al.: Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 1999, 45:1133-1141.
38. Wen PY, Brandes AA: Treatment of recurrent highgrade gliomas. Curr Opin Neurol 2009 Sep 18 (Epub ahead of print).
39. Mandl ES, Dirven CM, Buis DR, et al.: Repeated surgery for glioblastoma multiforme: Only in combination with other salvage therapy. Surg Neurol 2008, 69:506-509. discussion 509.
40. Cavaliere R, Wen PY, Schiff D: Novel therapies for malignant gliomas. Neurol Clin 2007, 25:1141-1171.
41. Rich JN, Reardon DA, Peery T, et al.: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22:133-142.
42. van den Bent MJ, Brandes AA, Rampling R, et al.: Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group Study 26034. J Clin Oncol 2009, 27:1268-1274.
43. Chang SM, Wen P, Cloughesy T, et al.: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005, 23:357-361.
44. Galanis E, Buckner JC, Maurer MJ, et al.: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 2005, 23:5294-5304.
45. Batchelor T, Sorensen G, di Tomaso E, et al.: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma [abstract LB-247]. Presented at the 99th Annual Meeting of the American Association for Cancer Research. San Diego, CA; April 12-16, 2008.
46. Batchelor TT, Sorensen AG, di Tomaso E, et al.: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
47. Wen PY, Cloughesy T, Kuhn J, et al.: Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02) [abstract 2006]. Presented at the 45th Annual Meeting for the American Society of Clinical Oncology. Orlando, FL; May 29-June 2, 2009.
48. Neyns B, Chaskis C, Dujardin M, et al.: Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma [abstract 2038]. Presented at the 45th Annual Meeting for the American Society of Clinical Oncology. Orlando, FL; May 29-June 2, 2009.
49. Quant EC, Norden AD, Drappatz J, et al.: Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 2009, 11:550-555.